Last updated on April 2019

Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients that are Treatment Naive or Receiving Bruton s-Tyrosine Kinase Inhibitor (BTK-I) Therapy


Brief description of study

Background:

  • People who have cancer tend to get sick more often. This is in part because of the cancer treatments they get. Because of this, they may get shingles. Scientists had thought people with chronic lymphocytic leukemia (CLL) should not get the shingles vaccine. Now there is a new shingles vaccine that is not live and cannot cause shingles. The new shingles vaccine may protect people with weak immune systems from getting shingles. This is currently shown to be safe to give people 50 years and older to prevent shingles. Researchers want to test how safe the vaccine is and how it works in people with CLL.

Objective:

  • To learn how a new shingles vaccine works in people who have chronic lymphocytic leukemia or small lymphocytic lymphoma (SLL).

Eligibility:

  • Adults ages 18 years and older with CLL or SLL who are not being treated for CLL or who are getting certain treatments.

Design:

  • Participants will be screened with a chart review or through another protocol.
  • Visit 1
    • At visit 1, participants may have a pregnancy test, blood test, or physical exam.
    • Pregnant participants cannot be in the study.
    • Eligible participants will get the shingles vaccine as an injection.
    • Participants will receive a diary and write down any sumptoms they have for 7 days after the vaccines.
  • Visit 2
    • Visit 2 will be 3 months later. Participants will have blood taken and get another dose of the vaccine.
    • Participants will receive a diary and write down any symptoms they have for 7 days after the vaccines.
  • Visit 3
    • Visit 3 will be 3 months after visit 2. Participants will have blood taken.
    • Participants may be able to get an additional vaccine the same day as the shingles vaccine.

 

Detailed Study Description

This study aims to determine the efficacy of the SHINGRIX varicella zoster virus (VZV) vaccine in chronic lymphocytic leukemia (CLL) patients that are treatment naive or receiving Bruton s-tyrosine kinase inhibitor (BTK-I) therapy.

Key Eligibility Criteria:

  • Diagnosis of CLL
  • Cohort 1: Treatment naive CLL patients
  • Cohort 2: Subjects must be receiving ibrutinib monotherapy for at least 6 months prior to administration of the first vaccine dose
  • Cohort 3: Subjects must be receiving acalabrutinib monotherapy for at least 6 months prior to administration of the first vaccine dose
  • Age greater than or equal to 18 years
  • ECOG performance status of 0-1

Design:

Patients with CLL will enroll on the study for the purpose of determining the SHINGRIX vaccine efficacy in patients who are treatment naive or receiving BTK-I therapy. A series of 2 doses of SHINGRIX will be given at 0- and 3- month schedule by intramuscular injection. Subjects will be followed for 6 months and receive assessment of serologic response 6 months after the first vaccine dose administration.

Study Objectives:

Primary Objective:

  • Determine the serologic response against VZV after completing the SHINGRIX (RZV) 2-dose vaccine series in the following populations:
    • CLL patients that are treatment naive (n=54)
    • CLL patients receiving treatment with ibrutinib (n=27)
    • CLL patients receiving treatment with acalabrutinib (n=27)

Secondary Objective:

  • Determine the safety and tolerability of the SHINGRIX vaccine among CLL patients who are treatment naive or receiving BTK-Is (ibrutinib or acalabrutinib).

 

Clinical Study Identifier: TX218184

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.